ESC 2026 preview: AstraZeneca/Ionis' Wainua trial miss, Cytokinetics' aficamten push into nHCM, and Novartis' pacibekitug in focus after Novo's IL-6 flop.
AstraZeneca, Ionis, Cytokinetics, Novartis and CRISPR Therapeutics, among others, will get a sense of the market potential of their heart drugs when data is presented …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key…
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb…
